PT-141 (Bremelanotide) Half-Life, Stability and Pharmacokinetics in Research
RESEARCH PT-141 (Bremelanotide) Half-Life, Stability and Pharmacokinetics in Research Bremelanotide, a synthetic melanocortin receptor agonist, exhibits a terminal half-life of approximately 2.7 hours in human clinical models [1]. Its pharmacokinetic profile is defined by rapid absorption and systemic clearance, distinct from traditional monoamine-based pathways [1]. Compound identity: CAS 189691-06-3 · C50H68N14O10 · 1025.2 g/mol (verified via PubChem)
The Pharmacokinetic Profile of Bremelanotide
Bremelanotide, known in research circles as PT-141, represents a departure from traditional pharmacologic approaches to central nervous system signaling. Unlike earlier compounds that targeted the vascular system, PT-141 acts as a non-selective agonist at the melanocortin receptors, specifically the MC3R and MC4R [1]. In human clinical trials, the compound demonstrates a predictable pharmacokinetic trajectory following subcutaneous administration [1]. The plasma concentration of the compound peaks with a median time to maximum concentration (Tmax) of approximately 1 hour [1]. Following this peak, the compound undergoes systemic distribution and elimination. The terminal elimination half-life is measured at roughly 2.7 hours, a figure derived from human pharmacokinetic studies [1]. These data points are essential for researchers mapping the temporal window of receptor engagement during experimental protocols.
Metabolism and Systemic Clearance
The metabolic fate of PT-141 is characterized by extensive hydrolysis, a process that breaks the peptide chain into smaller, inactive fragments [1]. Human clinical data confirms that the compound does not rely on cytochrome P450 enzymes for its primary metabolic clearance, which suggests a lower potential for the drug-drug interactions often seen with small-molecule pharmaceuticals [1]. Because the compound is a cyclic heptapeptide, its structural integrity is sensitive to the surrounding chemical environment. Researchers must account for the fact that the primary route of elimination is through the urine, with approximately 65% of the compound recovered in an unchanged form in human excretion studies [1]. The remaining fraction is processed through metabolic pathways that are currently less defined in the literature, leaving the specific identity of all secondary metabolites an open question for future biochemical investigation [1].
Stability and Formulation Considerations
In a laboratory setting, the stability of PT-141 is highly dependent on the solvent and storage conditions. As a peptide, the molecule is susceptible to degradation through hydrolysis and oxidation if exposed to improper temperatures or pH levels. While the FDA-approved formulation utilizes a specific aqueous solution designed for long-term stability, experimental research often requires the use of lyophilized (freeze-dried) powder to maintain structural integrity over extended periods [1]. The literature provided does not delineate the specific degradation rates of PT-141 when reconstituted in non-standard buffers or exposed to varying thermal stressors. Consequently, researchers typically rely on standardized cold-chain storage protocols to prevent the denaturation of the peptide chain. The absence of data regarding the stability of the compound in various experimental solvents means that researchers must verify the molecular weight and purity of their specific samples through analytical techniques like HPLC and mass spectrometry before initiating any study.
Evidence Grades and Clinical Context
It is vital to distinguish between the different tiers of evidence surrounding PT-141. The pharmacokinetic data, including the 2.7-hour half-life, is derived from human clinical trials [1]. These studies provide the most robust evidence for how the compound behaves in a biological system. Conversely, much of the foundational work on melanocortin receptor activation was established through earlier animal models and in-vitro receptor binding assays [1]. While the RECONNECT phase 3 trials provided significant data regarding the efficacy and safety profile of the compound in human subjects, these trials were focused on therapeutic outcomes rather than exhaustive pharmacokinetic mapping [2]. Therefore, while we have a clear picture of the half-life and clearance, other aspects of the compound’s long-term systemic impact remain under active investigation. Researchers should be cautious not to extrapolate the findings of phase 3 clinical trials—which are specific to the therapeutic context—to broader, unstudied physiological applications [2].
The Boundaries of Current Research
Despite the clarity on half-life and primary metabolic pathways, there are significant gaps in the current literature. For instance, the exact mechanism by which PT-141 crosses the blood-brain barrier to exert its effects on the central nervous system is still a subject of ongoing theoretical modeling [1]. While the compound is known to activate MC4R in the hypothalamus, the precise kinetics of this receptor-ligand interaction in vivo are not fully quantified in the provided sources. Furthermore, while the safety profile has been documented in large-scale human trials, the literature does not address the long-term consequences of repeated, high-frequency exposure in non-therapeutic research models [2]. The literature provided does not characterize the potential for receptor desensitization or downregulation following chronic, high-dose administration [2].
Frequently asked questions
What is the half-life of PT-141? Based on human clinical pharmacokinetic studies, the terminal elimination half-life of PT-141 is approximately 2.7 hours [1]. Does PT-141 interact with cytochrome P450 enzymes? No, the research indicates that PT-141 does not undergo significant metabolism via the cytochrome P450 pathway, as it is primarily cleared through hydrolysis and renal excretion [1]. How is PT-141 cleared from the body? Human studies show that approximately 65% of the administered compound is excreted in the urine in an unchanged form, indicating that renal clearance is a primary pathway [1]. Is the half-life the same in all research models? The 2.7-hour half-life is specific to human clinical data [1]. Pharmacokinetic profiles can vary significantly between species; therefore, this figure may not be directly applicable to animal models or in-vitro systems. What factors affect the stability of the compound? As a peptide, PT-141 is sensitive to environmental factors such as pH, temperature, and exposure to light, which can lead to hydrolysis or oxidation [1]. Proper storage of lyophilized material is essential to maintain its structural integrity.
Verification and Material Integrity
In the pursuit of reproducible data, the quality of the research material is the primary variable. Researchers typically verify the identity and purity of their samples by requesting a Certificate of Analysis (COA) that includes high-performance liquid chromatography (HPLC) and mass spectrometry results. These documents confirm the molecular weight and the presence of any impurities, ensuring that the compound being utilized matches the specifications required for the study. By tracking lot numbers and maintaining rigorous storage protocols, investigators can ensure that their experimental results are based on stable, chemically consistent material, thereby minimizing the noise that often plagues peptide-based research. Research use only. The compounds discussed are supplied for laboratory research and are not for human or veterinary use. Nothing on this page is medical advice, a dosing guide, or a claim about any product sold here; it summarises published research and cites its sources.
References
Authoritative sources cited for research context. Research use only — not medical advice.
